Announces new research results and join hands with Biotechnology Center, Zishe Association and Hanxun Technology to cultivate AI digital health talents Taipei, March 22, 2018 /PRNewswire/-Artificial intelligence will contribute US$15.7 trillion in the global economy in 2030.

Insilico TaiwanEngke Intelligent Asia AI R&D Base was established and guests gathered at the press conference.

Insilico Taiwan Insilico Taiwan will focus on the development and verification services of the ‘GAN’ in the future, strengthen deep learning of the application of medicinal chemistry, and continue to work closely with major Asian biotechnology, pharmaceutical and skin care companies. In view of the thirst for AI talents in Taiwan, Taiwan Yingke Intelligent's first wave of action is to form a cooperative alliance with Biotechnology Center, the Finance Association, and Hanxun Technology to carry out the "A.I. Digital Health Talent Cultivation Plan". The AI ​​biomedical, blockchain, and big data-related courses jointly developed mainly to integrate cross-domain talents in venture communication and biomedical medicine, accelerate the acquisition of artificial intelligence technology and drug development schedule, effectively reduce the risk of high R&D costs, and deepen artificial intelligence technology into Taiwan.

attracted nearly 100 heavyweights including AI, biotechnology, Zitong Technology, venture capital and other heavyweights to attend this wave of future AI digital health acceleration train. It included Hu Betty, Deputy Director of the Small and Medium Enterprises Department of the Ministry of Economics, Wu Zhongxun, CEO of the Biotechnology Center, Yang Ziqing, Deputy Director of the Digital Education Institute of Zicehui, Director of the Institute of Chemistry of the Central Academy of Research, Chen Yuru, General Manager of Hanxun Technology, Xu Mingkuan, Executive Director of the International Biomedical Industry and Academic Alliance of Taipei Medical University, and Dr. Zavolongkov, Director of the Industrial Development Department of the Biotechnology Center, and Dr. Huang Yuhua, Director of the "Global AI Digital Health and Blockchain Integration" Summit, witnessing the most important historical moment of the development of Taiwan's AI biomedical industry.

Hu Betty, Director of the Small and Medium Enterprises Department of the Ministry of Economy, said that the Ministry of Economy has been supporting the Biotechnology and Development Center for many years and provides support for enterprises to start businesses and innovate. This time, Insilico successfully entered the Nangang Biotechnology and Development Center, which is the best example of the resources of the Biomedical and Medicine Center for the integration of Biotechnology and Development Center. I believe that with Insilico's expertise and foresight in AI, combined with the resources and assistance of the Taiwan Nutrition Center, Taiwan will lead Taiwan to create a new era in the Asian biomedical industry. Wu Zhongxun, CEO of the Biotechnology Development Center of

consortium, pointed out that the cooperation case completed by the Biotechnology Center and Insilico Medicine last year is the first time in Taiwan to use AI technology to screen candidate drugs and design the structural design, allowing Taiwan's biomedical R&D team and international AI team to successfully combine the energy and expertise of both parties to conduct forward-looking drug development research and development cooperation. I believe that the excellent quality and solid training of Taiwan's biomedical talents, coupled with Taiwan's strong ICT foundation, are the main reasons that prompted Insilico Medicine to come to Taiwan to set up an Asian R&D center to grasp the major business opportunities of Asia.

Insilico Medicine, Dr. Alex Zhavoronkov, CEO of the United States Corporation of Insilico, said that we are pleased that "Asia's first AI R&D base" was officially established in Taiwan. Because Taiwan has rich medical and biotechnical talents, as well as strong drug R&D foundation and vertical integration capabilities, these energy will help us accelerate the vigorous development of the global biotechnical pharmaceutical industry. I am also very grateful to the Biotech Center for its recent support and close cooperation in AI biotech applications.

Dr. Zavoronkov pointed out that AI can assist in the development of the biomedical industry, including new drug development, medical material research and development, even molecular testing, genes, precision medicine, etc. Through AI introduction, it is estimated that the original drug research and development can be shortened from 10-20 years to 3-5 years, and the cause can be accurately compared and the success rate of drug development can be improved. In addition, environmental issues caused by waste toxic substances derived from original chemical synthesis and animal protection humanitarian issues caused by traditional animal experiments can also have the opportunity to greatly reduce or even eliminate them. By using the Blockchain technology, it can also improve the confidentiality prevention and control of drug research and development and information collection of etiology data.

Insilico TaiwanArtur Kadurin, CEO of Taiwan Insilico Taiwan, said that he is very happy to come to Taiwan to form an AI deep learning team to integrate and develop an ecological system that is in line with local drug discovery. Taiwan has been leading the world in the field of information and communications in the past. I believe that such a foundation of cooperation will help accelerate the future miracle of Taiwan and Asia's biotechnology pharmaceutical industries in the future. Taiwan Yingke Intelligent Future R&D Center in Taiwan will provide five major technical services, including the R&D application of artificial intelligence in drugs and biomarkers, network generation of new generation chemical structure reconstruction, path analysis of deep feature extraction, evaluation engine of basic chemical structure in deep learning, reinforcement learning and prediction, etc., to deeply cultivate the Asian market and give full play to its professionalism in artificial intelligence technology and biomedical medicine.

Kang Yatu added that in this wave of artificial intelligence digital transformation, in addition to having the advantages of traditional medicine in the field of traditional Chinese medicine, Taiwan also has excellent technologies and knowledge in Western medicine, such as AI for drug discovery/design and Agent (Agent) Research and Blockchain, such as the use of AI's superior computing technology, coupled with the combined infusion of industry, official, academic and research resources, will inevitably carry forward AI in combination with biomedical and medical, push Taiwan's industry to another peak, and create a win-win situation.

Artificial intelligence combined with biomedical industry has played an important role in the development of global biotechnology in recent years, and has become an important technical key for various countries to compete for development. I believe that after Taiwan's Yingke Intelligent's AI drug research and development base has entered the Nangang Software Park, it will accelerate close cooperation with legal entities and the biomedical industry, which can make greater contributions to the well-being of all mankind. At the same time, it can also provide digital R&D technology services for Taiwan's pharmaceutical and biotechnology industry, assist the biotechnology industry in introducing innovative elements, and make Taiwan a representative place for Asia's chief AI artificial intelligence combined with biomedical industry.